Zinzino AB Earnings Call Transcripts
Fiscal Year 2025
-
Q4 2025 saw 45% growth, driven by strong organic and acquisition-fueled expansion, especially in Central Europe. Gross margin improved, and management targets above 20% annual growth and 11%+ EBITDA margin, with integration of major acquisitions underway.
-
Q3 2025 saw robust growth and margin improvement, with Central Europe and North America leading performance. A new gut health test launch and successful acquisitions boosted results, while regulatory compliance remains a focus.
-
Q2 saw 57% growth (47% organic), strong cash flow, and robust performance across most regions, driven by tech investments, product innovation, and M&A. Management is confident in achieving a 10% margin for the year and maintaining profitable growth.
-
Q1 saw 59% year-over-year revenue growth, driven by organic expansion, acquisitions, and strong performance in Central Europe, North America, and Asia-Pacific. Subscription revenue remains robust, and new market entries and product launches are expected to fuel continued growth.